155 related articles for article (PubMed ID: 18630997)
1. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
Tepmongkol S; Keelawat S; Honsawek S; Ruangvejvorachai P
Thyroid; 2008 Jul; 18(7):697-704. PubMed ID: 18630997
[TBL] [Abstract][Full Text] [Related]
2. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
Kebebew E; Lindsay S; Clark OH; Woeber KA; Hawkins R; Greenspan FS
Thyroid; 2009 Sep; 19(9):953-6. PubMed ID: 19678746
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
Kebebew E; Peng M; Reiff E; Treseler P; Woeber KA; Clark OH; Greenspan FS; Lindsay S; Duh QY; Morita E
Surgery; 2006 Dec; 140(6):960-6; discussion 966-7. PubMed ID: 17188145
[TBL] [Abstract][Full Text] [Related]
4. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
5. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
Fatourechi V; Hay ID; Javedan H; Wiseman GA; Mullan BP; Gorman CA
J Clin Endocrinol Metab; 2002 Apr; 87(4):1521-6. PubMed ID: 11932275
[TBL] [Abstract][Full Text] [Related]
6. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
Bachelot A; Leboulleux S; Baudin E; Hartl DM; Caillou B; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2005 Mar; 62(3):376-9. PubMed ID: 15730423
[TBL] [Abstract][Full Text] [Related]
7. Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
Elias AN; Lizotte P
Clin Nucl Med; 2006 Sep; 31(9):517-9. PubMed ID: 16921272
[TBL] [Abstract][Full Text] [Related]
8. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
[TBL] [Abstract][Full Text] [Related]
10. Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning.
Caballero-Calabuig E; Cano-Terol C; Sopena-Monforte R; Reyes-Ojeda D; Abreu-Sánchez P; Ferrer-Rebolleda J; Sopena-Novales P; Plancha-Mansanet C; Félix-Fontestad J
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1449-56. PubMed ID: 18418591
[TBL] [Abstract][Full Text] [Related]
11. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
12. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of thyroglobulin changes for the efficacy of thyroid remnant ablation.
Savelli G; Chiti A; Rodari M; Schreiner F; Maccauro M; Aliberti G; Gerali A; Bombardieri E
Tumori; 2001; 87(1):42-6. PubMed ID: 11669557
[TBL] [Abstract][Full Text] [Related]
14. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
Philips JC; Petite C; Willi JP; Buchegger F; Meier CA
Nucl Med Commun; 2004 Dec; 25(12):1183-6. PubMed ID: 15640776
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
16. [Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
Martín T; Torres A; Cambil T; Castro J
Med Clin (Barc); 2008 Oct; 131(11):435. PubMed ID: 18928727
[No Abstract] [Full Text] [Related]
17. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
18. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.
Frank RW; Middleton L; Stack BC; Spencer HJ; Riggs AT; Bodenner DL
Head Neck; 2014 Feb; 36(2):155-7. PubMed ID: 23728951
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.
Omür O; Akgün A; Ozcan Z; Sen C; OzkiIiç H
Clin Nucl Med; 2009 Jan; 34(1):11-4. PubMed ID: 19092374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
